全文获取类型
收费全文 | 9842篇 |
免费 | 443篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 98篇 |
儿科学 | 199篇 |
妇产科学 | 215篇 |
基础医学 | 2232篇 |
口腔科学 | 146篇 |
临床医学 | 640篇 |
内科学 | 1581篇 |
皮肤病学 | 197篇 |
神经病学 | 1155篇 |
特种医学 | 454篇 |
外科学 | 1178篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 543篇 |
眼科学 | 225篇 |
药学 | 844篇 |
2篇 | |
中国医学 | 10篇 |
肿瘤学 | 564篇 |
出版年
2022年 | 59篇 |
2021年 | 117篇 |
2020年 | 100篇 |
2019年 | 116篇 |
2018年 | 122篇 |
2017年 | 105篇 |
2016年 | 139篇 |
2015年 | 181篇 |
2014年 | 233篇 |
2013年 | 258篇 |
2012年 | 431篇 |
2011年 | 480篇 |
2010年 | 267篇 |
2009年 | 277篇 |
2008年 | 444篇 |
2007年 | 452篇 |
2006年 | 442篇 |
2005年 | 445篇 |
2004年 | 466篇 |
2003年 | 427篇 |
2002年 | 435篇 |
2001年 | 161篇 |
2000年 | 146篇 |
1999年 | 144篇 |
1998年 | 98篇 |
1997年 | 93篇 |
1996年 | 70篇 |
1995年 | 61篇 |
1994年 | 63篇 |
1992年 | 86篇 |
1991年 | 79篇 |
1990年 | 70篇 |
1989年 | 79篇 |
1988年 | 76篇 |
1986年 | 59篇 |
1985年 | 68篇 |
1982年 | 56篇 |
1940年 | 70篇 |
1939年 | 56篇 |
1938年 | 71篇 |
1937年 | 81篇 |
1936年 | 73篇 |
1935年 | 68篇 |
1932年 | 60篇 |
1930年 | 59篇 |
1928年 | 59篇 |
1925年 | 57篇 |
1924年 | 64篇 |
1923年 | 55篇 |
1922年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Boehlen Friederike H. Maatouk Imad Friederich Hans-Christoph Schoettker Ben Brenner Hermann Wild Beate 《Quality of life research》2022,31(7):2023-2033
Quality of Life Research - Health-related quality of life (HRQOL) in older persons is influenced by physical and mental health, as well as by their social contacts and social support. Older women... 相似文献
62.
Vitamin D food fortification in European countries: the underused potential to prevent cancer deaths
Niedermaier Tobias Gredner Thomas Kuznia Sabine Schöttker Ben Mons Ute Lakerveld Jeroen Ahrens Wolfgang Brenner Hermann 《European journal of epidemiology》2022,37(4):309-320
European Journal of Epidemiology - Background: Meta-analyses of randomized controlled trials have shown that vitamin D supplementation reduces cancer mortality by 13%. Vitamin D fortification of... 相似文献
63.
Kerstin Kempf Martin Rhling Winfried Banzer Klaus Michael Braumann Martin Halle David McCarthy Hans Georg Predel Isabelle Schenkenberger Susanne Tan Hermann Toplak Aloys Berg Stephan Martin 《Nutrients》2021,13(5)
Lifestyle interventions, including meal replacement, are effective in the prevention and treatment of type-2-diabetes and obesity. Since insulin is the key weight regulator, we hypothesised that the addition of meal replacement to a lifestyle intervention reduces insulin levels more effectively than lifestyle intervention alone. In the international multicentre randomised controlled ACOORH (Almased Concept against Overweight and Obesity and Related Health Risk) trial, overweight or obese persons who meet the criteria for metabolic syndrome (n = 463) were randomised into two groups. Both groups received nutritional advice focusing on carbohydrate restriction and the use of telemonitoring devices. The intervention group substituted all three main meals per day in week 1, two meals per day in weeks 2–4, and one meal per day in weeks 5–26 with a protein-rich, low-glycaemic meal replacement. Data were collected at baseline and after 1, 3, 6 and 12 months. All datasets providing insulin data (n = 446) were included in this predefined subanalysis. Significantly higher reductions in insulin (−3.3 ± 8.7 µU/mL vs. −1.6 ± 9.8 µU/mL), weight (−6.1 ± 5.2 kg vs. −3.2 ± 4.6 kg), and inflammation markers were observed in the intervention group. Insulin reduction correlated with weight reduction and the highest amount of weight loss (−7.6 ± 4.9 kg) was observed in those participants with an insulin decrease > 2 µU/mL. These results underline the potential for meal replacement-based lifestyle interventions in diabetes prevention, and measurement of insulin levels may serve as an indicator for adherence to carbohydrate restriction. 相似文献
64.
65.
Carolin Lepa Sascha Hoppe Antje Stber Boris V. Skryabin Laura Katharina Sievers Barbara Heitplatz Giuliano Ciarimboli Ute Neugebauer Maja T. Lindenmeyer Clemens D. Cohen Hannes C.A. Drexler Peter Boor Thomas Weide Hermann Pavenstdt Britta George 《Journal of the American Society of Nephrology : JASN》2021,32(2):357
BackgroundInjury to kidney podocytes often results in chronic glomerular disease and consecutive nephron malfunction. For most glomerular diseases, targeted therapies are lacking. Thus, it is important to identify novel signaling pathways contributing to glomerular disease. Neurotrophic tyrosine kinase receptor 3 (TrkC) is expressed in podocytes and the protein transmits signals to the podocyte actin cytoskeleton.MethodsNephron-specific TrkC knockout (TrkC-KO) and nephron-specific TrkC-overexpressing (TrkC-OE) mice were generated to dissect the role of TrkC in nephron development and maintenance.ResultsBoth TrkC-KO and TrkC-OE mice exhibited enlarged glomeruli, mesangial proliferation, basement membrane thickening, albuminuria, podocyte loss, and aspects of FSGS during aging. Igf1 receptor (Igf1R)–associated gene expression was dysregulated in TrkC-KO mouse glomeruli. Phosphoproteins associated with insulin, erb-b2 receptor tyrosine kinase (Erbb), and Toll-like receptor signaling were enriched in lysates of podocytes treated with the TrkC ligand neurotrophin-3 (Nt-3). Activation of TrkC by Nt-3 resulted in phosphorylation of the Igf1R on activating tyrosine residues in podocytes. Igf1R phosphorylation was increased in TrkC-OE mouse kidneys while it was decreased in TrkC-KO kidneys. Furthermore, TrkC expression was elevated in glomerular tissue of patients with diabetic kidney disease compared with control glomerular tissue.ConclusionsOur results show that TrkC is essential for maintaining glomerular integrity. Furthermore, TrkC modulates Igf-related signaling in podocytes. 相似文献
66.
The Role of Growth Factors in the Control of Neurogenesis 总被引:2,自引:0,他引:2
Rohrer H 《The European journal of neuroscience》1990,2(12):1005-1015
67.
Susanne Danhauser-Riedl Edith Hausmann Hans-D. Schick Rita Bender Hermann Dietzfelbinger Johann Rastetter Axel-R. Hanauske 《Investigational new drugs》1993,11(2-3):187-195
Coupling of anthracyclines to high-molecular-weight carriers may alter drug disposition and improve antitumor effects. We have performed a clinical phase I trial of doxorubicin coupled to dextran (70000 m.w.). The drug was administered as single dose i.v. every 21–28 days. Thirteen patients have received a total of 24 courses (median 2; range 1–3). At the starting dose of 40 mg/m2 doxorubicin equivalent (DOXeq), WHO grade IV thrombocytopenia was noted in 2/2 patients. WHO grade IV hepatotoxicity and WHO grade III cardiotoxicity were noted in a patient with preexisting heart disease. Five patients were treated with 12.5 mg/m2 DOXeq. Maximal toxicity at this dose level was WHO grade III thrombocytopenia and local phlebitis (WHO grade II) in 1/5 patients, elevation of alkaline phosphatase (WHO grade III) and WHO grade III vomiting in another patient. Subsequently, five patients received 20 mg/m2 DOXeq. Hepatotoxicity was noted in 5/5 patients (1 × WHO grade IV, 1 × WHO grade III). Thrombocytopenia was noted in 3/5 patients (1 × WHO grade IV, 2 × WHO grade III). At 12.5 mg/m2 DOXeq, a patient diagnosed with a malignant fibrous histiocytoma had stable disease for 4 months. Pharmacokinetic analyses of total and free doxorubicin were performed in plasma and urine. The maximum peak plasma concentration (ppc) for total DOX was 12.3 g/ml at 40 mg/m2 DOXeq. The area under the plasma concentration time curve (AUC) ranged from 28.83–80.21 g/ml*h with dose-dependent elimination half lives (t1/2: 0.02–0.87 h;1/2: 2.69–11.58 h;1/2: 41.44–136.58 h). We conclude that the maximal tolerated dose (MTD) of AD-70 using this schedule is 40 mg/m2 DOXeq. The recommended dose for clinical phase II studies is 12.5 mg/m2 DOXeq.Abbreviations ALT
Alanine Aminotransferase
- AST
Aspartate Aminotransferase
- DOX
Doxorubicin
- DOXeq
Doxorubicin Equivalent
- ECG
Electrocardiogram
- HPLC
High Pressure Liquid Chromatography
- LD10
Lethal Dose for 10% of individuals
- MTD
Maximal Tolerated Dose
- ppc
Peak Plasma Concentration
- WHO
World Health Organisation 相似文献
68.
D. Steiner B. Hermann 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》1990,375(1):19-23
Zusammenfassung Die polarisationsoptische and histologische Untersuchung des oberen Bicepssehnenabschnittes an 26 Schultern bestätigt, daß die Sehne ihren Ursprung nicht nur, wie allgemein angenommen, am Tuberculum supraglenoidale hat, sondern außerdem -förmig im Labrum glenoidale. Dieser Befund kann phylogenetisch erklärt werden. Im weiteren Verlauf der Sehne können neue Befunde im Bereich des Sulcus bicipitalis erhoben werden. Hier ist regelmäßig ein Mesotenonium nachweisbar, das durch einen bindegewebigen Ausläufer an Sulcusdach oder -grund befestigt ist. Darüberhinaus wird gezeigt, daß das Sulcusdach nicht als Ligament (Ligamentum transversum humeri) anzusprechen ist, es handelt sich vielmehr um Ausläufer der Kollagenfasern von Subscapularis- bzw. Kapselansatz am Tuberculum minus.
Topography of the upper biceps tendon
Summary 26 shoulders are studied by polariscopic and histologic examination. It can be confirmed that the origin of the long biceps tendon is not only at the supraglenoid tubercle, but also -shaped in the glenoid labrum. This finding can be explained by phylogenetic means. Further details are found during the course of the tendon through the bicipital groove. A mesotenonium is seen regularly. This is fixed either to the roof or the ground of the sulcus by a band of connective tissue. It is shown also, that the roof of the groove is not a ligament (ligamentum transversum. humeri) but consists of collagen fibers continuing from the subscapularis and capsular attachment at the lesser tubercle.相似文献
69.
Walther Seiler Hermann Wetzel Andreas Hillert Günter Schöllnhammer Michael Langer Uwe Barlage Christoph Hiemke 《Psychopharmacology》1994,116(4):457-463
Pharmacokinetics and bioavailability of benperidol were determined in 13 schizophrenic patients after acute administration of 6 mg benperidol as an intravenous (i.v.) bolus injection, orally as liquid, and orally as tablets using a partially randomized cross-over design. Drug plasma levels were determined by high performance liquid chromatography with electrochemical detection and subjected to model independent pharmacokinetic analyses. After i.v. dosing the geometric means (mean-g) were 3.2 min for the distribution half-life, 5.80 h for the elimination half-life (t
1/2), 4.21 l/kg for the distribution volume, 7.50 h for the mean residence time (MRT), and 0.50 l/(h*kg) for the clearance. After oral administration as liquid and as tablet mean-g data for the time lag until the first appearance of measurable plasma concentrations were 0.33 and 1.1 h, mean-g
t
1/2 values were 5.5 and 4.7 h, respectively, mean-g t
max data were 1.0 h and 2.7 h, mean-g MRT values were 8.44 and 8.84 h, and mean-g C
max
maxvalues were 10.2 and 7.3 ng/ml. Differences between liquid and tablet administration were statistically significant for time lag,t
max, andC
max. Mean-g absolute bioavailabilities were computed as 48.6% after liquid and 40.2% after tablet administration respectively. All parameters studied exhibited large intersubject variation. The plasma concentrations of the presumed metabolite reduced benperidol were found to be very low. 相似文献
70.